ClinicalTrials.gg
RecruitingNCT06923657Updated May 28, 2026

PSMA PET/MRI-Guided Prostate Biopsy for PI-RADS ≤3 and Prior Negative Biopsy

An interventional study of PSMA PET/MRI-TRUS guided prostate targeted combined saturation biopsy and TRUS guided transperineal saturation biopsy in Prostate Cancer Screening and PSMA-PET, sponsored by First Affiliated Hospital of Fujian Medical University. Recruiting at 1 site in China. Open to male participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by First Affiliated Hospital of Fujian Medical University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
30 Years to 85 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Prostatic Neoplasms by First Affiliated Hospital of Fujian Medical University — 10 open to participants now, 13 under way, 1 of them phase 3. Prostatic Neoplasms · First Affiliated Hospital of Fujian Medical University.

Planned enrollment
3rd of 13
230 · median 40
Started
2025
with 5 others
No phase
2 of 15
2 open now
Primary completion
2026-09
later than 5 of 12 live
Registered
6th of 15
by date

Among the 15 studies in Prostatic Neoplasms by First Affiliated Hospital of Fujian Medical University, this one is the 3rd largest by planned enrollment of the 13 interventional ones that give a count, is one of 6 that started in 2025, is one of 2 with no phase, reaches primary completion later than 5 of the 12 other live ones, and was the 6th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

10 of the 15 studies in Prostatic Neoplasms by First Affiliated Hospital of Fujian Medical University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 30 Years to 85 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Prostatic Neoplasms by First Affiliated Hospital of Fujian Medical University, or all of them as a file.
02

Study summary

The goal is to provide more accurate diagnostic tools and optimized diagnostic workflows for clinically suspected prostate cancer patients with prior negative biopsies, improving early detection rates for csPCa and reducing missed diagnoses.

Read the detailed description

This research intends to prospectively enroll patients with prior negative biopsies, a PI-RADS score ≤ 3, and persistent PSA or PHI elevation, randomly assigning them to the PSMA PET/MRI group (experimental group) and the TRUS-guided transperineal saturation biopsy group (control group). The research aims to evaluate the application of PSMA PET/MRI in clinically suspected prostate cancer patients with prior negative biopsies, comparing the differences in csPCa detection rates between PSMA PET/MRI-TRUS guided prostate targeted biopsy and TRUS-guided saturation biopsy.

03

Conditions studied

  • Prostate Cancer Screening
  • PSMA-PET

Browse trials for

Keywords

  • imaging examinations
  • PSMA PET/MRI
  • Prostate cancer
04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Serum PSA > 4 ng/mL
  • At least one prior negative prostate
  • At least two consecutive increases in PSA and/or PHI
  • Negative digital rectal examination
  • Multiparametric MRI (mpMRI) indicating a PI-RADS score ≤ 3

Exclusion criteria

Exclusion Criteria

  • Age ≤ 30 years or > 85 years
  • Concurrent presence of other malignant tumors
  • Previous treatment with any form of anti-tumor therapy or prostate surgery (excluding prostate )
  • Inability to comply with PSMA PET/MRI examination (e.g., contrast allergy, claustrophobia, etc.)
  • for prostate biopsy (e.g., coagulation disorders, acute prostatitis, acute urinary tract infection, etc.)
  • Severe organ dysfunction (e.g., significant cardiac, pulmonary, hepatic, or renal impairment)
  • Incomplete clinical or pathological data
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
230 participants (estimated)

Study arms

  • Active comparator
    The control group

    The control group will receive TRUS guided transperineal saturation biopsy.

    Diagnostic Test: TRUS guided transperineal saturation biopsy

  • Experimental
    The experimental group

    The experimental group will undergo PSMA PET/MRI examination. For those with positive PSMA PET/MRI results, a PSMA PET/MRI-TRUS guided prostate targeted biopsy will be performed based on transrectal ultrasound (TRUS) guided transperineal saturation biopsy, targeting the positive lesions. For those with negative PSMA PET/MRI results, only TRUS guided transperineal saturation biopsy will be performed.

    Diagnostic Test: PSMA PET/MRI-TRUS guided prostate targeted combined saturation biopsy

Interventions

  • Diagnostic testPSMA PET/MRI-TRUS guided prostate targeted combined saturation biopsy

    The experimental group will undergo PSMA PET/MRI examination. For those with positive PSMA PET/MRI results, a PSMA PET/MRI-TRUS guided prostate targeted biopsy will be performed based on transrectal ultrasound (TRUS) guided transperineal saturation biopsy, targeting the positive lesions. For those with negative PSMA PET/MRI results, only TRUS guided transperineal saturation biopsy will be performed. Clinical and pathological data of the patients will be collected for statistical analysis.

  • Diagnostic testTRUS guided transperineal saturation biopsy

    The control group will receive TRUS guided transperineal saturation biopsy. Clinical and pathological data of the patients will be collected for statistical analysis.

06

What researchers measure

Primary outcomes

  1. Diagnostic Sensitivity

    It refers to the percentage of patients who actually have prostate cancer correctly identified as positive (true positive). The calculation formula is: TP/(TP+FN)×100%. TP is true positive, and FN is false negative.

    Time frame: Perioperative

  2. Diagnostic Specificity

    It refers to the percentage of patients who do not actually have prostate cancer correctly identified as negative (true negative). The calculation formula is: TN/(TN+FP)×100%. TN is true negative, and FP is false positive.

    Time frame: Perioperative

  3. Positive Predictive Value(PPV)

    It refers to the proportion of true positives among the positive results obtained by a specific testing method. The calculation formula is: PPV = TP/(TP+FP)×100%.

    Time frame: Perioperative

  4. Negative Predictive Value(NPV)

    It refers to the proportion of true negatives among the negative results obtained by a specific testing method. The calculation formula is: NPV = TN/(TN+FN)×100%.

    Time frame: Perioperative

  5. Positive Likelihood Ratio(PLR)

    It refers to the ratio of the probability of correctly identifying a patient with prostate cancer as positive to the probability of incorrectly identifying a patient without prostate cancer as positive. The calculation formula is: +LR = Sensitivity / (1- Specificity)×100%.

    Time frame: Perioperative

  6. Negative Likelihood Ratio(NLR)

    It refers to the ratio of the probability of incorrectly identifying a patient with prostate cancer as negative to the probability of correctly identifying a patient without prostate cancer as negative. The calculation formula is:-LR = (1- Sensitivity) / Specificity×100%.

    Time frame: Perioperative

  7. Correct Diagnostic Index

    It refers to the sum of sensitivity and specificity minus 1. The correct diagnostic index can be used for comparing two diagnostic methods, with an ideal correct diagnostic index of 100%.r = (Specificity+Sensitivity) -1 = 1- (False Positive Rate + False Negative Rate).

    Time frame: Perioperative

Secondary outcomes

  1. PRECISION Questionnaire

    The incidence of complications for the two biopsy methods.

    Time frame: 1 week before biopsy, 1 week after biopsy, 1 month, 3 months, 6 months, 12 months.

  2. EORTC QLQ-C30 Questionnaire

    The change in quality of life compared to baseline values in the experimental group and control group.

    Time frame: Before diagnosis, 1 month, 3 months, 6 months, 12 months

  3. Generalized Anxiety Disorder GAD-7 Scale

    The difference in anxiety levels at each time point between the experimental group and the control group.

    Time frame: Before diagnosis, 1 week after diagnosis, 1 month, 3 months, 6 months, 12 months

  4. Decision Conflict Scale, Decision Regret Scale

    The decision-making differences at each time point between the experimental group and the control group.

    Time frame: Before diagnosis, 1 month, 3 months, 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Sep 2026, 15 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 15 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2025
First posted
Apr 11, 2025
StartActual
May 7, 2025
Primary completionEst.
Sep 1, 2026
CompletionEst.
Dec 1, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06923657
Lead sponsor
First Affiliated Hospital of Fujian Medical University
Responsible party
Ning Xu (Deputy Director of Department, First Affiliated Hospital of Fujian Medical University) — Principal investigator
First posted
Apr 11, 2025
Start date
May 7, 2025
Primary completion
Sep 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
May 28, 2026

Study contacts

Ning Xu
Contact
drxun@fjmu.edu.cn
13235907575 ext. 0086

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion